Inventor · disambiguated record
Alan F. List
Also filed as: LIST ALAN · LIST ALAN F
22 granted patents·24 pending applications·73 citations·filing 1995–2025
93Inventor score
Files withH LEE MOFFITT CANCER CT & RES35PREC BIOSCIENCES INC4LIST ALAN F2DUGAN MARGARET H1H LEE MOFFITT CANCER CENTER AND RES INSITUTE INC1
Top patents by PatentIndex Score
46 records- 0197US11976104B2TLR9 ligand trapH LEE MOFFITT CANCER CT & RES·Filed 2021·Granted May 7, 2024·6 cites·10 claims
- 0286US10071094B2Protein phosphatase 2A inhibitors for treating myelodysplastic syndromesH LEE MOFFITT CANCER CT & RES·Filed 2015·Granted Sep 11, 2018·7 cites·19 claims
- 0385US11286306B2TLR9-binding chimeric antigen receptorsH LEE MOFFITT CANCER CT & RES·Filed 2017·Granted Mar 29, 2022·4 cites·17 claims
- 0484US10434100B2Protein phosphatase 2A inhibitors for treating myelodysplastic syndromesH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Oct 8, 2019·5 cites·20 claims
- 0581US11584787B2Soluble CD33 for treating myelodysplastic syndromes (MDS)H LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Feb 21, 2023·1 cites·16 claims
- 0677US10488411B2Inflammasome activation in myelodysplastic syndromesH LEE MOFFITT CANCER CT & RES·Filed 2016·Granted Nov 26, 2019·1 cites·12 claims
- 0776US2023348555A1Soluble cd33 for treating myelodysplastic syndromes (mds)H LEE MOFFITT CANCER CT & RES·Filed 2023·Application pending·0 cites
- 0876US2025115641A1Stapled peptides as pyrin-domain targeted nlrp3 inflammasome inhibitorsH LEE MOFFITT CANCER CT & RES·Filed 2024·Application pending·0 cites
- 0975US10697970B2S100A9 levels for predicting lenalidomide and erythropoietin responsivenessH LEE MOFFITT CANCER CT & RES·Filed 2016·Granted Jun 30, 2020·1 cites·9 claims
- 1074US9487776B2Method of identifying myelodysplastic syndromesLIST ALAN F·Filed 2012·Granted Nov 8, 2016·5 cites·22 claims
- 1173US11280787B2Inflammasome activation in myelodysplastic syndromesH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Mar 22, 2022·0 cites·13 claims
- 1272US12077608B2Stapled H2 pyrin peptidesH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Sep 3, 2024·0 cites·2 claims
- 1372US10344072B2Soluble CD33 for treating myelodysplastic syndromes (MDS)H LEE MOFFITT CANCER CT & RES·Filed 2014·Granted Jul 9, 2019·1 cites·15 claims
- 1471US5846958AMethods of using aminothiols to promote hematopoietic progenitor cell growthUS BIOSCIENCE·Filed 1995·Granted Dec 8, 1998·32 cites·13 claims
- 1570US10682417B2Targeted sensitization of non-del(5q) malignant cellsH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Jun 16, 2020·0 cites·12 claims
- 1669US9956294B2Targeted sensitization of non-del(5q) malignant cellsH LEE MOFFITT CANCER CT & RES·Filed 2014·Granted May 1, 2018·0 cites·7 claims
- 1768US2022040263A1Companion diagnostic for combination lenalidomide and erythropoietin treatmentH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 1867US2025257065A1Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitorsH LEE MOFFITT CANCER CT & RES·Filed 2025·Application pending·0 cites
- 1966US2022144897A1Chimeric tim-3 fusion proteinH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 2064US2022143193A1TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLSH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 2163US12319685B2Small molecule pyrin-domain targeted NLRP3 inflammasome inhibitorsH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Jun 3, 2025·0 cites·13 claims
- 2263US2025041417A1Methods for cancer immunotherapyPREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2363US2019167803A1Tlr9 targeted cytotoxic agentsH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 2463US2025009800A1Methods for cancer immunotherapyPREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2562US10612097B2RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDSH LEE MOFFITT CANCER CT & RES·Filed 2017·Granted Apr 7, 2020·0 cites·8 claims
- 2660US9738933B2RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDSH LEE MOFFITT CANCER CT & RES·Filed 2013·Granted Aug 22, 2017·0 cites·8 claims
- 2760US2020354471A1Tetravalent tlr9 bispecific antibodyH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 2860US2020354331A1Icariin derivativesH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 2959US2019240290A1Companion diagnostic for combination lenalidomide and erythropoietin treatmentH LEE MOFFITT CANCER CT & RES·Filed 2017·Application pending·0 cites
- 3057US11123435B2TLR9 targeted therapeuticsH LEE MOFFITT CANCER CT & RES·Filed 2017·Granted Sep 21, 2021·0 cites·5 claims
- 3157US2021024582A1Chimeric tim-3 fusion proteinH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 3257US2022323433A2Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitorLIST ALAN F·Filed 2022·Application pending·0 cites
- 3356US10688077B2Inflammasome activation in myelodysplastic syndromesH LEE MOFFITT CANCER CT & RES·Filed 2016·Granted Jun 23, 2020·0 cites·11 claims
- 3455US2023190780A1Methods for immunotherapyPREC BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3554US2017333565A1Tlr9 targeted cytotoxic agentsH LEE MOFFITT CANCER CT & RES·Filed 2015·Application pending·0 cites
- 3653US11287428B2PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemiaH LEE MOFFITT CANCER CT & RES·Filed 2017·Granted Mar 29, 2022·0 cites·9 claims
- 3753US2019111053A1Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitorLIXTE BIOTECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 3852US5906984AMethods of using aminothiols to promote hematopoietic progenitor cell growthUNIV ARIZONA·Filed 1998·Granted May 25, 1999·10 cites·22 claims
- 3951US2022088073A1Chimeric antigen receptors with enhanced tumor infiltrationH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 4051US2022041682A1Tlr9-targeted therapeuticsH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 4147US2023192807A1Methods for immunotherapyPREC BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4243US2017335009A1Tetravalent tlr9 bispecific antibodyH LEE MOFFITT CANCER CT & RES·Filed 2015·Application pending·0 cites
- 4341US2006128716A1Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromesDUGAN MARGARET H·Filed 2003·Application pending·0 cites
- 4440US2017044127A1Icariin derivativesH LEE MOFFITT CANCER CT & RES·Filed 2015·Application pending·0 cites
- 4538US2020115358A1Icariin and icaritin derivativesH LEE MOFFITT CANCER CT & RES·Filed 2017·Application pending·0 cites
- 4637US11361867B2Pathways for treating patientsH LEE MOFFITT CANCER CENTER AND RES INSITUTE INC·Filed 2013·Granted Jun 14, 2022·0 cites·29 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →